|
| Press Releases |
|
 |
|
| Wednesday, October 14, 2020 |
|
|
Hua Medicine Announces the Drug Manufacturing Permit Granted for Dorzagliatin |
Hua Medicine (the "Company", Stock Code: 2552.HK) announces that, after review and on-site verification under the Marketing Authorization Holder ("MAH") system, the Company has obtained the drug manufacturing permit for dorzagliatin, its investigational first-in-class drug, issued by the Shanghai Municipal Drug Administrative Bureau.
more info >> |
|
| Monday, August 17, 2020 |
|
|
Bayer and Hua Medicine announce commercialization agreement and strategic partnership for investigational first-in-class novel diabetes treatment dorzagliatin in China |
| Bayer and Hua Medicine, a leading innovative drug development company, today announced a commercialization agreement and strategic partnership for dorzagliatin, a novel diabetes treatment, in China. more info >> |
|
| Wednesday, July 1, 2020 |
|
|
Hua Medicine Announces Positive 24-Week Topline Results of Phase III Metformin Combination Trial of Dorzagliatin |
| Hua Medicine today announced the positive 24-week top-line results from HMM0302, a Phase III registration trial in China of its global first-in-class glucokinase activator dorzagliatin add-on to metformin, a first line oral antidiabetic therapy in Type 2 diabetes. more info >> |
|
| Thursday, June 18, 2020 |
|
|
Hua Medicine Successfully Completes SEED (HMM0301), Dorzagliatin Phase III Monotherapy Trial |
| Hua Medicine (the "Company", Stock Code: 2552.HK), a leading innovative drug development company focused on developing novel therapies for the treatment of diabetes, today announced topline results from SEED (also known as HMM0301) more info >> |
|
| Monday, April 27, 2020 |
|
|
Hua Medicine Announces Positive Results in the Combination Study of Dorzagliatin with Empagliflozin (a SGLT-2 inhibitor) |
| Hua Medicine (the "Company", Stock Code: 2552. HK) today announces the positive results of the clinical study HMM0112. more info >> |
|
| Monday, March 16, 2020 |
|
|
Hua Medicine Announces 2019 Annual Results |
| Hua Medicine (the "Company", Stock Code on The Stock Exchange of Hong Kong Limited: 2552.HK), a global innovative drug research and development company focused on novel therapies for the treatment of diabetes, today announces the audited consolidated results of the Company and its subsidiaries for the year ended December 31, 2019. more info >> |
|
| Friday, February 14, 2020 |
|
|
Hua Medicine appoints Dr. Fuxing Tang, a former U.S. FDA Officer, as Chief Technology Officer |
| Hua Medicine, a leading clinical stage biotechnology company based in Shanghai, is pleased to announce that Dr. Fuxing Tang has joined Hua Medicine as Chief Technology Officer, VP of Formulation R&D and Product Development. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Shoucheng Interim Results: Revenue +36%, Asset Finance +69%, Robot Focus
Aug 31, 2025 20:40 HKT/SGT
|
|
|
Hong Kong Watch & Clock Fair, Salon de TIME return in September
Aug 31, 2025 12:30 JST
|
|
|
Genetec reinforces foundation for growth, maintains resilient outlook
Aug 30, 2025 23:59 HKT/SGT
|
|
|
Integrated Development of Four Major Businesses to Drive the Financial 'Five Major Areas', GF Securities Announces its 2025 Interim Results
Aug 30, 2025 16:08 HKT/SGT
|
|
|
Global New Material International Establishes Asia-Pacific Headquarters in Hangzhou, Advancing Global Integration
Aug 30, 2025 10:54 HKT/SGT
|
|
|
Gome Retail's H1 2025 Significant Performance Improvement, Debt Resolution Breakthrough, and Accelerated Strategic Transformation
Aug 29, 2025 22:15 HKT/SGT
|
|
|
CITIC Limited reports solid H1 2025 results with higher dividend
Aug 29, 2025 20:51 HKT/SGT
|
|
|
AI-Powered Foundation, Innovation-Driven Empowerment, Legend Holdings Reports RMB699 Million in Net Profit Attributable to Parent for 2025H1
Aug 29, 2025 19:13 HKT/SGT
|
|
|
Honda Announces New Plan for Relocation of Global Head Office to Yaesu Area in Tokyo and Reconstruction of Honda Aoyama Building
Aug 29, 2025 18:54 JST
|
|
|
Analogue 2025 Interim Results Net Profit Reaches HK$80.8 Million
Aug 29, 2025 17:42 HKT/SGT
|
|
|
Black Spade calls for family offices to increase their focus on digital assets and emerging industries 
Aug 29, 2025 17:32 HKT/SGT
|
|
|
Ministry Of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Anticancer Agent Tazemetostat for Unresectable INI1-Negative Epithelioid Sarcoma
Aug 29, 2025 18:17 JST
|
|
|
TechInnovation 2025 Returns with 3 Days of Game-Changing Innovation
Aug 29, 2025 16:00 HKT/SGT
|
|
|
Hitachi Energy acquires remaining stake of eks Energy, reinforcing leadership in power conversion systems for energy storage
Aug 29, 2025 15:17 JST
|
|
|
JF SmartInvest Holdings Ltd Returns to Profit in 2025 Interim Results
Aug 29, 2025 11:24 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
